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ABSTRACT
Stroke becomes world health problem all over the world because it is the causal factor of high
mortality and disability. Good and well-organized process of healthcare service will improve the
outcome of the patients with stroke. Clinical pathway may be used as clear standard to help reduce
unnecessary variations of medical treatment and measure. The study aimed at finding out the
correlation between the use of clinical pathway and the outcome of the patients with ischemic stroke
in Bethesda Hospital Yogyakarta. It was an observational and analytic study with cohort restorative
study design. The author compared the outcomes of acute ischemic stroke between the group with
clinical pathway and the group without the clinical pathway. Data was collected using consecutive
sampling from the electronic registry and medical record data of the patients from January 1st, 2011
to December 31st, 2011. It was conducted to 124 patients with ischemic stroke assigned to two
groups (the first groups of 62 patients with clinical pathway and the second groups of 62 patients
without clinical pathway). The basic characteristics of the two groups were the same. The results of
the analysis showed that there was a significant decrease in the incidence of complication and a
significant increase in the use of antiplatelete drugs, antidiabetic drugs and statin as secondary
preventive measure of the recurrent stroke. There was not any significant difference in the duration
of the hospitalized healthcare, the financing and the mortality between the two observation groups.
In conclusion, the study indicated that the use of the clinical pathway in the stroke treatment
improves the outcome of the patients with stroke and that it is necessary to conduct further study to
evaluate the effectiveness of the clinical pathway in improving the outcome of the patients with
bigger number of the subjects and longer period of time.
ABSTRAK
Stroke menjadi masalah kesehatan utama di seluruh dunia, karena menyebabkan angka kematian dan
kecacatan yang tinggi. Proses pelayanan yang baik yaitu lebih terorganisir akan memperbaiki luaran
pasien stroke. Clinical pathway dapat dimanfaatkan sebagai standar yang jelas untuk membantu
mengurangi variasi yang tidak perlu dari perawatan dan tindakan medis. Tujuan dari penelitian ini
adalah untuk mengetahui hubungan pemberlakuan clinical pathway dengan luaran pasien stroke
iskemik di rumah sakit Bethesda, Yogyakarta. Penelitian ini merupakan penelitian observasional analitik
dengan rancangan penelitian cohort retrospective. Peneliti membandingkan luaran stroke iskemik
akut antara kelompok yang menggunakan clinical pathway dengan kelompok yang tidak. Data
diambil dengan consecutive sampling dari data register stroke elektronik pasien dan rekam medis
antara 1 Januari 2011 sampai dengan 31 Desember 2011. Penelitian diperoleh dari 124 pasien
stroke iskemik (62 pasien dengan clinical pathway dan 62 pasien tanpa clinical pathway). Karakteristik
dasar dari kedua kelompok sama. Hasil analisis menunjukkan bahwa ada penurunan angka kejadian
komplikasi dan peningkatan penggunaan obat antiplatelet, antidiabetes dan statin sebagai tindakan
pencegahan sekunder agar stroke tidak berulang. Tidak ada perbedaan bermakna dalam hal lama
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rawat inap, pembiayaan dan kematian diantara dua kelompok pengamatan. Penelitian ini
menunjukkan bahwa pemberlakuan clinical pathway pada pelayan stroke memperbaiki luaran
pasien stroke. Penelitian lebih lanjut sangat diperlukan untuk menilai efektivitas clinical pathway
terhadap luaran pasien dengan jumlah subyek yang lebih banyak dan jangka waktu yang lebih
lama.
Keywords: clinical pathway - stroke - outcomes
INTRODUCTION
Stroke becomes main health problem all
over the world because it is the causal factor of
high mortality and disability. In Indonesia, it
ranks the highest in causing death, followed by
diabetes mellitus and hypertension in both rural
and urban areas.1 Good and well-organized
healthcare service process such as the one in
the stroke unit will improve the outcome of the
patients with stroke because it decreases
mortality risk in a year.2 It is possible that
multidisciplinary healthcare service in the
stroke unit result in various medical measures
prone to malpractices.
Clinical pathway may be used as clear
standard to help reduce unnecessary variations.
The clinical pathway or care pathway or critical
pathway is a healthcare service planning concept
that aims at improving the efficiency of the
healthcareserviceorganizationfor thepatientswith
stroke in which the healthcare service is delivered
in multidisciplinarymanner onscientific evidence
with medical care standard.3,4
The clinical pathway to handle the patients
with stroke in Bethesda Hospital,Yogyakarta has
been introduced since the beginning of 2008. It
was in check list form for easier use, memorizing
and evaluation.An initial study by Pinzon et al.5
that have examined the effectiveness of the use of
theclinicalpathwayinthemanagementof167patients
withstrokeinBethesdaHospital,Yogyakartashowed
that the use of the clinical pathway significantly
improved the indicators of the process of the
healthcare service for the patients with stroke.
Therefore, the study was conducted to find out the
effectiveness of the use of the clinical pathway in
improving the outcome of the patients with
ischemic stroke in Bethesda Hospital,Yogyakarta.
MATERIALS AND METHODS
Protocol of the study
It was an observational and analytic study
with retrospective cohort design to compare the
outcome of the patients in twoobservationgroups.
Data was collected using consecutive sampling
technique fromtheelectronic registryand medical
record data from January 1st, 2001 to December
31st, 2011. The patients were classified into case
group of ischemic stroke and got the first stroke
used clinical pathway, had complete registry and
medical record data and also complete
observation. They were assigned to control group
if they met the inclusion and exclusion criteria in
thecasegroup,butdidnotuse theclinicalpathway.
They were excluded from the study if they
experienced the variants such as forced discharge,
changing hospital, cared in ICU and requiring
decompression operation. The protocol of the
study has been approved by the Medical and
Health Research Ethics Committee, Universitas
Gadjah Mada, Yogyakarta.
The outcome of the study included the use of
drugs,mortality,complicationincidence, functional
status,hospitalizationduration,andtotalhealthcare
cost. The functional status was evaluated using
modifiedrankingscale(MRS)thatwasmadewhen
thepatientsweredischargedfromthehospital.The
outcomes in dichotomous form were good (MRS
< 2) and bad (MRS > 2).
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Statistical analysis
The results of this study were analyzed using
data processing software. For comparisons of
dichotomous outcomes, the relative risk (RR)
with their 95% confident interval (CI) was
calculated. Calculated the exact p value was
used Yates-corrected chi-square test and
Fisher’s exact test.The outcome with continuous
data was first checked the data for normality of
distribution. For normally distributed data,
comparison of means was performed using and
independent t-test; otherwise, the non parametric
Mann-Whitney U test was used. For outcome
measures that could be influenced by case mix,
the data was adjusted using logistic regression.
RESULTS
Based on the registry data, there were 406
patients with ischemic stroke and got the first
seizure. They were assigned to 2 groups, which
were control group (n=250) of those without
clinical pathway in the treatment and case group
(n=156) of those with clinical pathway.The study
data selection process was illustrated in the
FIGURE 1.
FIGURE 1. The flowchart of the study data selection process
Based on the data summarized in TABLE 1,
it could be concluded that the basic characteristics
as age, sex, clinical symptom, comorbid disease,
GCS score, Charlson index, and the care ward of
the two cohorts were equal.
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TABLE 1. Basic characteristics of study subjects
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TABLE 1. Basic characteristics of study subjects (continued)
Thesecondarypreventionoftheischemicstroke
was conducted using drugs such as antiplatelete,
anticoagulant, antidiabetes, statin, and
antihypertensiontohandletheriskfactor.Additionally,
TABLE. 2. Bivariate analysis of factors of drug use
the use of vitamins and neuroprotectors was also
analyzedin thestudybecause theywereoftenused.
The results of the analysis of the use of each of the
drugsweresummarizedinTABLE2.
Note : Ref = Reference; a) tested by Pearson Chi-Square; b) tested by Fisher’s Exact Test; CI=Confident
Interval
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The resultsoftheanalysis inTABLE2showed
that theuseoftheclinicalpathwayincreasedtheuse
of antiplatelete (100% vs. 90.3%, p= 0.028),
antidiabetes (35.5%vs.17.7%,p=0.025)andstatin
(75.8% vs. 45.2%, p= 0.000) as compared to the
non-clinicalpathwaygroup,whiletherewasnotany
significantdifferenceintheuseofanticoagulantand
antihypertension between the two observation
groups. TABLE 2 also indicated that the use of
vitaminswaslowerintheclinicalpathwaygroupthan
inthenon-clinicalpathway,while therewasnotany
significantdifferenceintheuseoftheneuroprotectors
between the twogroups.
TABLE 3 showed that the use of the clinical
pathway was able to decrease the complication
incidence in the patients with stroke as compared
to the control group (3.2 % vs 14.5%, p = 0.027).
However, there was not any significant difference
in the mortality (6.5% vs 1.6%, p = 0.365),
functional status (use of the clinical pathway
(25.8% vs 40.3%, p = 0.086) between the two
observation groups.
TABLE 3. Bivariate analysis of the outcome
Note : Ref = Reference; a)tested by Pearson Chi-Square; b) tested by Fisher’s Exact Test; CI=Confident
Interval
Nosignificantdifference in thehospitalization
duration between the two cohorts was observed.
Similarly, there was also not any significant
difference in the total cost for the patients during
the hospitalization between the twogroups though
the mean costs of the clinical pathway was lower
than the control group (i.e., the mean difference
was 492.136; 95% Confident Interval
-3.147.457 – 163.185).
TABLE 4. Bivariate analysis of clinical pathway implementation on length of stay
Note : Ref = Reference
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TABLE 5. Bivariate analysis to total cost the implementation of clinical pathways
Note : Ref = Reference
DISCUSSION
It was observed in the study that the use of
the clinical pathway increased the use of
antiplatelete, which was higher than the subjects
without any clinical pathway in their treatment
process. The result was similar to that of the study
conducted by Wolf et al.6 However, the result is
different fromthat of the studyconductedbyTylor
et al.7 The use of the clinical pathway in the
treatment of the patients with stroke increased the
use of antidiabetes and statin as indicated and
compared to those without any clinical pathway,
but the study conducted byTaylor et al.7 indicated
the contrary.
Bivariateanalysisof theriskfactorof theuseof
anticoagulantinthepatientswithischemicstrokeand
atrial fibrillation showed that the use of the clinical
pathwaycouldnot increase theuseofanticoagulant
as compared to the group without any clinical
pathway.It isconsistentwiththestudyconductedby
Taylor et al.7Also, the results of the studyhave not
beenabletoproofthattheuseoftheclinicalpathway
could increase the use of antihypertension. It is
consistentwiththestudyconductedbyTaylor etal.7
andKwanetal.8 thoughafter theuseofthepathway
there were more patients found to use the
antyhypertensiondrugs.
The useof theclinical pathwaycould increase
the rationality of the use of the drugs such as
antiplatelete, antidiabetes and statin in the patients
with stroke because the function of the clinical
pathway was as reminder and it contained the
summary of the data necessary for physicians and
paramedics responsible for the treatment of the
patients.4,9,10
The use of vitamins and neuroprotectors in
the study was analyzed because they were often
used in the treatment of the patients with stroke.
The results of the study indicated that the use of
the vitamins in the case group was lower than the
control group. The neuroprotectors used in the
studywereciticolineandpiracetam.However, they
were not analyzed separately. There was not any
significant difference in the use of the
neuroprotectors between the two cohorts. There
was not any improvement of the functional status
and not any decrease in the mortality between the
two groups. It is consistent with some studies
suggesting that the use of the neuroprotectors did
not improve the functional status of the patients
with stroke.11,12
The results of the studyshowed that there was
not any significant difference in the mortality
between the two groups. It is similar to the finding
of the study conducted byTaylor et al.7 and Kwan
et al.8 The influencing factor of the mortality
indicated in the study was the GCS score < 8.
There were more patients with the GCS < 8 who
died because of organ malfunction that gave them
onlysmall life expectancy.
The study showed that the use of the clinical
pathway could decrease the complication
incidence in the patients with stroke. It was
consistent with the study conducted by Kwan et
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al.8 indicating that there were smaller number of
the patients in the group with the pathway were
affected by urethra infection than the patients
without the pathway. However, there were more
complicationsresultingfromtheuseofantiplatelete
and anticoagulant that caused the hemorrhage of
digestive line that mostly affected the groups of
the patients without any clinical pathway as
compared to the group with the clinical pathway.
The use of statin was more for the protection
against complication than thesubjects whodid not
use the statin. It protected the patients against the
hemorrhageofthedigestivelinebecauseit increased
theproductionofprostacyclinandprostaglandinthat
functiontoprotect thedigestivelinewall.13
The symptom of decreasing consciousness
was proven to increase the risk of complication
incidence.Therefore, the patientsexperiencing the
decreasingconsciousness were in need for special
treatment such as the insertion of urinary catheter,
the use of NGT or tracheostomy that could
increase the complication incidence, prolong the
hospitalizationperiodand influence the functional
status of the affected patients.14,15
The use of the clinical pathway in the study
did not show any effectiveness in improving the
functionality of the patients when they were
discharged from the hospital. The result is similar
that of the study conducted by Taylor et al.7,
although it is different with that of Sulch et al.16
Diabetes mellitus became the risk factor of
the decrease in the functionality of the patients
because hyperglycemia would cause the lactic
acidosis, the increase in excitatoric
neurotransmitter concentrationand the increase in
intracellular calcium that caused neurocellular
damage. Such hyperglycemia condition would
aggravate neurological deficit and increase
mortalityofboth thepatientswithdiabetesmellitus
and those with reactive hyperglycemia.17,18
The results of the studyshowed that there was
not any difference in the hospitalization duration
between the clinical pathway group and the non-
clinical pathway group. They were similar to the
study conducted by Taylor et al.7 They were
different from the study conducted byVan Exel et
al.19 suggesting that the integrated healthcare
service was able to shorten the hospitalization
duration of the patients with the clinical pathway
as compared to the control group. The presence
of the complication could prolong the
hospitalization duration because the patients
experiencing the complication were in need for
more intensive healthcare than those without the
complication that required longer hospitalization.8
Theresultsofbivariateanalysisofthefinancing
in the study have not proven that the use of the
clinical pathway in the healthcare of the patients
with stroke was able to decrease the cost
necessary to incur by the patients with the clinical
pathway than the control.Although the mean cost
necessary to incur by the patients with the clinical
pathway was lower than that necessary to incur
by the patients without any clinical pathway, there
was statistically not any significant difference
between the twogroups during the hospitalization.
This is not consistent with the study conducted by
VanExel etal.19 indicating that the financingof the
treatment of the patients with stroke was cheaper
in the group served using integrated healthcare
service. It was expected that it related to the
decrease in the hospitalization duration, which
resulted in thesignificant reductionofthe financing
of the treatment of the patients with the stroke.
The presence of the complication could
increase the financing by the patients and it was
not the case of the patients without any
complication. It was because the patients with the
complication required more intensive healthcare
and hence it increased the cost.Additionally, the
patientswerealso inneedfor longerhospitalization
period. Moreover, they had to consume more
anticoagulantdrugsandtheanticoagulantdrugsthat
were uses subcutaneously were relatively
expensive and it finally caused more financing by
the patients.
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Thestudyhasnotmanagedtofindtheevidence
that the use of the clinical pathway could decrease
the mortality and had significant impact on the
outcomes such as disabilities and the use of drugs.
It might result from the small number of samples
and the randomizedsampling technique that could
cause bias and the unavoidable presence of the
confounding factors that could have significant
impact on the validity of the results.Additionally,
the study was conducted simultaneously by the
same physicians and paramedics with the same
management of the two groups of patients.Also,
the important thing was that the condition of the
patientswith strokewas verycomplex and it could
have significant impact on the outcome.
CONCLUSION
The study indicated that the use of the clinical
pathwayin the treatmentof thepatientswithstroke
wasable todecreasecomplication.However, there
was not any significant difference in the mortality,
the functional status, the hospitalization duration,
and the financing between the two observation
groups.
The useof theclinical pathwaycould increase
the use of antiplatelete, antidiabetes, and statin as
the prevention measure of secondary stroke.
However, there was not any significant difference
in the use of antihypertension and anticoagulant.
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